Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND Part B: AEVI-001 in ADHD without mGluR Mutations
NCT03609619Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing AEVI-001 with Placebo (2 arms). Primary endpoint: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 Total Score at Week 6. Started Aug 2018; status: completed.
02
Drugs
fasoracetam
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03609619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03609619.